Get the Stockscreener App
2.04
7.69%
-0.17
After Hours:
2.05
0.010
+0.49%
Overview
News
Price History
Option Chain
Financials
Why SAVA Down?
Discussions
Forecast
Stock Split
Dividend History
Cassava Sciences Inc stock is traded at $2.04, with a volume of 1.29M.
It is down -7.69% in the last 24 hours and up +7.94% over the past month.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
See More
Previous Close:
$2.21
Open:
$2.21
24h Volume:
1.29M
Relative Volume:
1.57
Market Cap:
$98.55M
Revenue:
-
Net Income/Loss:
$-97.22M
P/E Ratio:
-1.4783
EPS:
-1.38
Net Cash Flow:
$-82.44M
1W Performance:
-13.19%
1M Performance:
+7.94%
6M Performance:
-5.56%
1Y Performance:
-26.09%
1-Day Range:
$2.01
$2.21
1-Week Range:
$2.01
$2.33
52-Week Range:
$1.15
$4.98
Cassava Sciences Inc Stock (SAVA) Company Profile
Name
Cassava Sciences Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Compare SAVA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
2.04 | 106.76M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Cassava Sciences Inc Stock (SAVA) Latest News
Momentum Shift: What dividend growth rate does Cassava Sciences Inc Equity Warrant offerJuly 2025 PreEarnings & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Cassava Sciences (SAVA) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
SAVA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cassava Sciences (NASDAQ:SAVA) Rating Lowered to Sell at Wall Street Zen - MarketBeat
SAVA SEC FilingsCassava Sciences 10-K, 10-Q, 8-K Forms - Stock Titan
Cassava Sciences Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Cassava Sciences says DOJ has closed probe into allegations around its Alzheimer’s program - MSN
Dow Update: Can Cassava Sciences Inc beat the S P 500July 2025 PreEarnings & Free Long-Term Investment Growth Plans - baoquankhu1.vn
SAVA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
MSN Money - MSN
Cassava Sciences says US DOJ has closed investigation into company - Classic Rock 103.5 WIMZ
DOJ closes inquiry into Cassava Sciences over research misconduct By Investing.com - Investing.com Canada
JNJ Stock Rises As Drugmaker Reportedly Eyes Orthopedics Segment Sale For Up To $20B - Stocktwits
Cassava Sciences Says DOJ Has Closed Probe Into Allegations Around Its Alzheimer’s Program - Asianet Newsable
Cassava Sciences stock rises after DOJ closes investigation By Investing.com - Investing.com Canada
Cassava Sciences DOJ Inquiry Closed, Legal Overhang Eased - TipRanks
Cassava says DoJ closed probe into research misconduct (SAVA) - Seeking Alpha
DOJ closes inquiry into Cassava Sciences over research misconduct - Investing.com
Cassava Sciences says DOJ closes inquiry after prior indictment dismissal - TradingView
Cassava Announces Closure of U.S. Department of Justice Investigation - The Manila Times
Cassava Sciences, Inc. Announces Closure of U.S. Department of Justice Investigation - marketscreener.com
Justice Dept closes Cassava research misconduct inquiry, ending federal probes - Stock Titan
DOJ closes probe into Cassava Sciences over Simufilam | Tap to know more | Inshorts - Inshorts
How sensitive is Cassava Sciences Inc. to inflation2025 Macro Impact & Growth Focused Entry Point Reports - mfd.ru
SAVA Should I Buy - Intellectia AI
Aug Outlook: Can Cassava Sciences Inc. (PX91) stock sustain revenue momentum2025 Market Outlook & AI Driven Price Predictions - mfd.ru
Fed Watch: What are Cassava Sciences Incs technical support levelsJuly 2025 Retail & High Win Rate Trade Tips - baoquankhu1.vn
Can Cassava Sciences Inc. Equity Warrant maintain its current growth rateJuly 2025 Opening Moves & Weekly Breakout Watchlists - mfd.ru
Cassava Sciences And 2 Other Promising Penny Stocks - Yahoo Finance
Cassava Sciences Target of Unusually High Options Trading (NASDAQ:SAVA) - MarketBeat
Is Cassava Sciences Inc. Equity Warrant stock a smart buy before Fed meetingJuly 2025 Movers & AI Powered Trade Plan Recommendations - mfd.ru
Cassava Sciences (NASDAQ:SAVA) Upgraded to Hold at Wall Street Zen - MarketBeat
Setup Watch: Is Cassava Sciences Inc Equity Warrant subject to activist investor interestJuly 2025 Gainers & Smart Swing Trading Alerts - baoquankhu1.vn
Is Cassava Sciences Inc. stock influenced by commodity prices2025 Bull vs Bear & High Accuracy Investment Signals - mfd.ru
What are Cassava Sciences Inc.’s technical support levelsJuly 2025 Analyst Calls & Expert Verified Stock Movement Alerts - mfd.ru
Stock Analysis: Does Cassava Sciences Inc Equity Warrant have pricing powerRecession Risk & Smart Money Movement Alerts - baoquankhu1.vn
Setup Watch: What is Cassava Sciences Inc Equity Warrants book value per shareGold Moves & High Accuracy Swing Trade Signals - baoquankhu1.vn
Cassava Sciences (NASDAQ:SAVA) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Retail Surge: What are the future prospects of Cassava Sciences Inc Equity Warrant2025 Retail Activity & Free Community Consensus Stock Picks - baoquankhu1.vn
The Truth About Cassava Sciences: Wall Street’s Wildcard Stock Everyone Keeps Arguing About - AD HOC NEWS
Aug Retail: What is Cassava Sciences Inc Equity Warrants book value per shareDollar Strength & Verified Trade Idea Suggestions - baoquankhu1.vn
Energy Moves: Is Cassava Sciences Inc backed by strong institutional buyingDay Trade & Daily Stock Trend Reports - baoquankhu1.vn
Cassava Sciences Inc - FOREX.com
Cassava Sciences publishes phase 3 Alzheimer’s trial results in JPAD By Investing.com - Investing.com Nigeria
RSI Check: How Cassava Sciences Inc stock trades during market volatilityEarnings Performance Report & Smart Swing Trading Alerts - Bộ Nội Vụ
Cassava Sciences publishes phase 3 Alzheimer’s trial results in JPAD - Investing.com
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease - Yahoo Finance
Cassava Announces Publication of Peer-Reviewed Phase 3 - GlobeNewswire
Will Cassava Sciences Inc. stock benefit from sector rotationMarket Trend Summary & Smart Money Movement Alerts - ulpravda.ru
What valuation multiples suggest for Cassava Sciences Inc. Equity Warrant stockJuly 2025 Summary & AI Based Buy and Sell Signals - ulpravda.ru
Cassava Sciences Inc Stock (SAVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cassava Sciences Inc Stock (SAVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barry Richard | President & CEO |
Nov 20 '25 |
Buy |
2.76 |
150,000 |
414,000 |
938,060 |
| Barry Richard | President & CEO |
Nov 19 '25 |
Buy |
2.75 |
73,385 |
201,809 |
788,060 |
| Cook Robert Christopher | Chief Operating & Legal Office |
Sep 30 '25 |
Buy |
2.91 |
13,725 |
39,940 |
13,725 |
| Barry Richard | President & CEO |
Sep 22 '25 |
Buy |
2.28 |
7,172 |
16,352 |
714,675 |
| Barry Richard | President & CEO |
Sep 18 '25 |
Buy |
2.24 |
190,633 |
426,424 |
660,195 |
| Barry Richard | President & CEO |
Sep 19 '25 |
Buy |
2.29 |
47,308 |
108,319 |
707,503 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):